ABO blood group distribution in migraine patients; the relationship of phenotypes with migraine subtypes, clinical features, and white matter lesions: a retrospective case-control study
Abstract
Migraine is a common and disabling neurological disorder with a complex and multifactorial pathophysiology. While genetic and vascular mechanisms have been extensively studied, the potential role of the ABO blood group system in migraine susceptibility and clinical characteristics remains unclear. This study aimed to evaluate the distribution of ABO and Rh blood groups in patients with migraine and to investigate their associations with migraine subtypes, clinical features, and white matter lesions (WMLs). This retrospective case–control study included 411 migraine patients aged 18–50 years and 4319 control individuals from the same geographical region. Migraine diagnosis and classification were established according to the International Classification of Headache Disorders, 3rd edition. ABO and Rh blood groups were determined using the gel centrifugation method. Migraine subtypes, clinical characteristics, and the presence of WMLs on cranial magnetic resonance imaging (MRI) were recorded. Group comparisons, univariate and multivariable logistic regression analyses, and a sensitivity analysis restricted to female participants were performed. Blood group B was significantly less frequent in migraine patients compared with controls (13.4% vs. 18.6%, p = 0.009; significant after Bonferroni correction). In multivariable logistic regression adjusting for age and sex, blood group B remained independently associated with lower odds of migraine (adjusted OR = 0.660, 95% CI:…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 4,319 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.